Avid Bioservices Inc (CDMO)

[vinmantoo]

The interim analysis showed that the bavituximab combination group is performing as expected according to the original trial assumptions in terms of overall survival, while the docetaxel group is dramatically outperforming overall survival expectations based on the original trial assumptions and as compared to recently published studies.

That is a very simple statement. Back it up or don't mention it. I don't know why you can't see how different that is from how any company I have invested in behaves or what BMS said. PPHM knows what the expectations were from their trial design, so just tell everyone what the results were. It astonishes me to no end that most longs don't seem to care when management says something like that and then 6 months later still hasn't backed it up, either by giving the MOS data that led them to make that comment, or even just the control arm MOS. How in the world would giving out just the control arm data compromise their "secrets"?